Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 7/2017

01-05-2017 | Therapy in Practice

The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies

Authors: Roy Lirov, Francis P. Worden, Mark S. Cohen

Published in: Drugs | Issue 7/2017

Login to get access

Abstract

Until recently, patients with advanced thyroid cancers had limited options for systemic treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class of targeted therapies for thyroid cancer, suddenly patients with advanced disease were given new options to extend survival. Guidelines worldwide have been updated to include general indications for these newer agents, but questions remain regarding which agent(s) to select, when to begin treatment, and how long therapy should continue. Additionally, the true impact of TKIs on overall survival and quality-of-life in thyroid cancer patients needs further clarification. As familiarity with approved agents and longer-term data become available, better strategies for implementation of these targeted drugs will evolve to optimize benefit for patients living with metastatic disease.
Literature
1.
2.
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2013/​, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
3.
4.
Aschebrook-kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21(2):125–34.PubMedPubMedCentralCrossRef
5.
Haddad RI, Lydiatt WM, Ball DW, et al. Anaplastic thyroid carcinoma, version 2.2015. J Natl Compr Canc Netw. 2015;13(9):1140–50.PubMedPubMedCentral
6.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.PubMedPubMedCentralCrossRef
7.
Tufano RP, Clayman G, Heller KS, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid. 2015;25(1):15–27.PubMedCrossRef
8.
Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.PubMedPubMedCentralCrossRef
9.
10.
Bible KC, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016;13(7):403–16.PubMedCrossRef
11.
Rajhbeharrysingh U, Taylor M, Milas M. Medical therapy for advanced forms of thyroid cancer. Surg Clin North Am. 2014;94(3):541–71.PubMedCrossRef
12.
Narayanan S, Colevas AD. Current standards in treatment of radioiodine refractory thyroid cancer. Curr Treat Options Oncol. 2016;17(6):30.PubMedCrossRef
13.
Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med. 2004;24(1):49–83.PubMedCrossRef
14.
Martins RG, Rajendran JG, Capell P, Byrd DR, Mankoff DA. Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol. 2006;24(11):1653–5.PubMedCrossRef
15.
Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):464–8.PubMedCrossRef
16.
Gottlieb JA, Hill CS. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974;290(4):193–7.PubMedCrossRef
17.
18.
19.
Viola D, Valerio L, Molinaro E, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185–205.PubMedCrossRef
20.
21.
Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.PubMedCrossRef
22.
23.
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.PubMedPubMedCentralCrossRef
24.
25.
26.
Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011;11:349.PubMedPubMedCentralCrossRef
27.
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.PubMedCrossRef
28.
Brose MS, Smit J, Capdevila J, et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12(9):1137–47.PubMedCrossRef
29.
Na’ara S, Amit M, Fridman E, Gil Z. Contemporary management of recurrent nodal disease in differentiated thyroid carcinoma. Rambam Maimonides Med J. 2016;7(1):1–7.
30.
Kwong N, Marqusee E, Gordon MS, et al. Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer. Endocr Connect. 2014;3(4):207–14.PubMedPubMedCentralCrossRef
31.
Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–13.PubMedPubMedCentralCrossRef
32.
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–72.PubMedPubMedCentralCrossRef
33.
Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–8.PubMedPubMedCentralCrossRef
34.
Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib: Phase II study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014;120(17):2694–703.PubMedCrossRef
35.
Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014;74(6):1261–70.PubMedPubMedCentralCrossRef
36.
Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99(5):1687–93.PubMedPubMedCentralCrossRef
37.
Bikas A, Kundra P, Desale S, et al. Phase II clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer. Eur J Endocrinol. 2016;174(3):373–80.PubMedCrossRef
38.
Atallah V, Hocquelet A, Do cao C, et al. Activity and safety of sunitinib in patients with advanced radioiodine refractory thyroid carcinoma: a retrospective analysis of 57 patients. Thyroid. 2016;26(8):1085–92.PubMedCrossRef
39.
Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–82.PubMedCrossRef
40.
Rothenberg SM, Mcfadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21(5):1028–35.PubMedCrossRef
41.
42.
Owonikoko TK, Chowdry RP, Chen Z, et al. Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. Oncologist. 2013;18(12):1262–9.PubMedPubMedCentralCrossRef
43.
Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23(5):600–4.PubMedPubMedCentralCrossRef
44.
Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014;99(6):2086–94.PubMedPubMedCentralCrossRef
45.
Massicotte MH, Brassard M, Claude-desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170(4):575–82.PubMedCrossRef
46.
Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418–20.PubMedCrossRef
47.
Worden F, Fassnacht M, Shi Y, et al. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer. 2015;22(6):877–87.PubMedPubMedCentralCrossRef
48.
Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905.PubMedCrossRef
49.
50.
Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014;24(10):1508–14.PubMedPubMedCentralCrossRef
51.
52.
53.
54.
Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165(2):315–22.PubMedCrossRef
55.
56.
Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44–53.PubMedCrossRef
57.
Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42.PubMedCrossRef
58.
Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27(23):3794–801.PubMedCrossRef
59.
60.
Frank-raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157(2):215–20.PubMedCrossRef
61.
De groot JW, Zonnenberg BA, Van ufford-mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466–9.PubMedCrossRef
62.
Daliri M, Abbaszadegan MR, Bahar MM, et al. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Endocr Res. 2014;39(4):189–93.PubMedCrossRef
63.
64.
Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923–31.PubMedCrossRef
65.
Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139–46.PubMedPubMedCentralCrossRef
66.
Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18(7):2056–65.PubMedPubMedCentralCrossRef
67.
68.
69.
70.
Carracedo A, Ma L, Teruya-feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065–74.PubMedPubMedCentral
71.
Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24(12):3089–94.PubMedCrossRef
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
Su DH, Chang SH, Chang TC. The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2015;82(2):286–94.PubMedCrossRef
95.
Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 2016;101(1):264–74.PubMedCrossRef
96.
Costa R, Carneiro BA, Chandra S, et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016;10:873–84.PubMedPubMedCentralCrossRef
97.
Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18(14):3722–30.PubMedCrossRef
98.
Robinson BG, Paz-ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2664–71.PubMedPubMedCentralCrossRef
99.
Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–72.PubMedPubMedCentralCrossRef
100.
Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–6.PubMedPubMedCentralCrossRef
101.
Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid. 2011;21(2):119–24.PubMedCrossRef
102.
Ali SM, He J, Carson W, et al. Extended antitumor response of a BRAF V600E papillary thyroid carcinoma to vemurafenib. Case Rep Oncol. 2014;7(2):343–8.PubMedPubMedCentralCrossRef
103.
Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40(3):210–3.PubMedCrossRef
104.
Kwon J, Wu HG, Youn YK, Lee KE, Kim KH, Park DJ. Role of adjuvant postoperative external beam radiotherapy for well differentiated thyroid cancer. Radiat Oncol J. 2013;31(3):162–70.PubMedPubMedCentralCrossRef
105.
Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):3179–84.PubMedPubMedCentralCrossRef
106.
107.
Montero-conde C, Ruiz-llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3(5):520–33.PubMedPubMedCentralCrossRef
108.
Reddi HV, Madde P, Cohen YC, et al. Antitumor activity of VB-111, a novel antiangiogenic virotherapeutic, in thyroid cancer xenograft mouse models. Genes Cancer. 2011;2(10):993–5.PubMedPubMedCentralCrossRef
109.
110.
111.
112.
Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid. 2009;19(9):953–6.PubMedCrossRef
113.
114.
115.
Sherman EJ, Su YB, Lyall A, et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid. 2013;23(5):593–9.PubMedPubMedCentralCrossRef
116.
117.
118.
Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18(3):317–23.PubMedCrossRef
119.
Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(1):164–70.PubMedCrossRef
120.
Harvey RD, Owonikoko TK, Lewis CM, et al. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. Br J Cancer. 2013;108(4):762–5.PubMedPubMedCentralCrossRef
121.
122.
123.
Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232–40.PubMedCrossRef
124.
125.
Lim SM, Chung WY, Nam KH, et al. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer. 2015;51(12):1588–95.PubMedCrossRef
126.
Dickson MA, Gordon MS, Edelman G, et al. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33(2):349–56.PubMedCrossRef
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
Czepczyński R, Matysiak-Grześ M, Gryczyńska M, et al. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp (Warsz). 2015;63(2):147–54.PubMedCrossRef
138.
Ibrahimpasic T, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2014;99:1245–52.PubMedCrossRef
139.
Schlumberger M, et al. Randomized, double-blinded, placebo controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)—exploratory analyses of patient-reported outcomes [abstract 100]. Presented at the 83rd Annual Meeting of the American Thyroid Association (2013).
140.
Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356–8.PubMedCrossRef
141.
Wassermann J, Bernier MO, Spano JP, et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist. 2016;21(1):50–8.PubMedCrossRef
Metadata
Title
The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies
Authors
Roy Lirov
Francis P. Worden
Mark S. Cohen
Publication date
01-05-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0733-1

Other articles of this Issue 7/2017

Drugs 7/2017 Go to the issue

Systematic Review

Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis

Current Opinion

Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors

Adis Drug Evaluation

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma

Review Article

Fentanyl Formulations in the Management of Pain: An Update

AdisInsight Report

Ribociclib: First Global Approval

AdisInsight Report

Telotristat Ethyl: First Global Approval